Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer
Lorbrena (lorlatinib) as initial treatment delayed disease progression at five years in more than half of people with ALK-positive metastatic non-small-cell lung cancer (NSCLC), according to study results presented Friday at the American Society of …